CME

Clinically Integrating Patient-Reported Outcomes into Acute Myeloid Leukemia Care Management

By November 27, 2019 No Comments
Clinically Integrating Patient-Reported Outcomes into Acute Myeloid Leukemia Care Management

Release Date: 11/8/2019
Expiration Date: 11/9/2020
Physicians – Maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses – 1.2 contact hours (0.4 pharmacotherapy)

VISIT ACTIVITY


The goal of this project is to identify the variety of symptoms relevant to patients receiving treatment for AML and test the electronic Patient Reported Outcomes (ePRO) tool in the clinical setting. A certified educational training on the latest clinical research and evidence-based guidelines for treating patients with AML is part of this study. The training will also include the ePRO survey tool and the evidenced-based guidelines for management of symptoms. Participating clinicians will evaluate feasibility of using the PRO tool and triage protocols compared to their standard of care approach.  

Target Audience

The target audience for this activity are U.S.-based medical oncologists, oncology Advanced Practice Providers, oncology nurses and nurse navigators. 

Educational Objectives

After completing this activity, the participant should be better able to:

  • CME/CNE Activity 1
    • Consider patient and disease characteristics to guide treatment selection for patients with AML 

    CME/CNE Activity 2

    • Apply the latest clinical findings and guideline recommendations to treatment selection for first and later lines of therapy
    • Appropriately and promptly manage side effects associated with the newly approved immunotherapeutic and anti-angiogenic agents used for the treatment of AML

Faculty

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM
Duke Cancer Institute 

Joint Accreditation Statement

Joint Accreditation CMEIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.  Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses. 

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Thomas W. LeBlanc, MD Consulting Fees: Abbvie, AstraZeneca, Agios, Amgen, Daiichi-Sankyo, Heron, Pfizer, Seattle Genetics; Commercial Interest FeesAgios, CelgeneContracted ResearchJazz Pharma, Seattle Genetics 

Planners and Managers

The PIM planners and managers have nothing to disclose. The Carevive Systems, Inc. planners and managers have nothing to disclose. 

Media

PowerPoint With Voiceover, Animated Video

Fee Information

There is no fee for this educational activity.

Instructions for Obtaining Credit

During the period November 8, 2019 through November 9, 2020, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-survey/evaluation. If you wish to receive acknowledgment for completing this activity, please complete the post-test with a passing score of 75% and the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search bycourse ID 14505. Once completed, your certificate will be made available immediately.  Click on View Certificate and print the certificate for your records. 

Computer System Requirements

Carevive Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content.  These activities will be marked as such and will provide links to the required software.  That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

 

Jointly provided by Postgraduate Institute for Medicine  and Carevive Systems, Inc. 
Grant funding provided by AbbVie, Inc. and Astellas Pharma US, Inc.

Postgraduate Institute for Medicine and Carevive Logos

 

 

Carevive Activity ID: G-435